UTHR

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · derivative · entry 7

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,500

Underlying: Common Stock · 6,000 shares

Expires 2026-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 6

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,599

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $216.06 to $216.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 5

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,799

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $215.02 to $215.695. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 4

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,325

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $214.00 to $214.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 3

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,847

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $212.98 to $213.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 2

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,124

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $211.80 to $212.255. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 1

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,599

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F2 · balance_after: Includes 112 shares acquired on March 3, 2023, under the United Therapeutics Corporation Employee Stock Purchase Plan.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · derivative · entry 18

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,000

Underlying: Common Stock · 8,000 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F9 · price: This transaction was executed in multiple trades at prices ranging from $219.225 to $220.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,813

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F8 · price: This transaction was executed in multiple trades at prices ranging from $218.21 to $219.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,803

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F7 · price: This transaction was executed in multiple trades at prices ranging from $217.10 to $218.085. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,554

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F6 · price: This transaction was executed in multiple trades at prices ranging from $216.06 to $217.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,042

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $214.77 to $215.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,776

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $213.77 to $214.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,262

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $212.73 to $213.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,740

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $211.695 to $212.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005217 · form4-03202023_040301.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · derivative · entry 18

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 264,000

Underlying: Common Stock · 8,000 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 14

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F13 · price: This transaction was executed in multiple trades at prices ranging from $220.255 to $220.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 13

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 419

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F12 · price: This transaction was executed in multiple trades at prices ranging from $219.25 to $219.925. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 12

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 919

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F11 · price: This transaction was executed in multiple trades at prices ranging from $218.115 to $219.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,251

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F10 · price: This transaction was executed in multiple trades at prices ranging from $217.09 to $217.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,652

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F9 · price: This transaction was executed in multiple trades at prices ranging from $216.09 to $217.085. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-005017 · form4-03162023_040304.xml · derivative · entry 4

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 2,000 shares

Expires 2024-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

SEC source: 0001415889-23-005017 · form4-03162023_040304.xml · nonDerivative · entry 2

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

SEC source: 0001415889-23-005017 · form4-03162023_040304.xml · nonDerivative · entry 1

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

SEC source: 0001231589-26-000005 · primarydocument.xml · derivative · entry 3

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,895

Underlying: Common Stock · 8,895 shares

Expires not disclosed

F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001231589-26-000005 · primarydocument.xml · derivative · entry 2

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,796

Underlying: Common Stock · 7,796 shares

Expires not disclosed

F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001231589-26-000005 · primarydocument.xml · derivative · entry 1

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,860

Underlying: Common Stock · 49,860 shares

Expires 2033-03-15

F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026.

SEC source: 0001106578-26-000001 · primarydocument.xml · derivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,080

Underlying: Common Stock · 37,080 shares

Expires not disclosed

F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001106578-26-000001 · primarydocument.xml · derivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,499

Underlying: Common Stock · 32,499 shares

Expires not disclosed

F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001106578-26-000001 · primarydocument.xml · derivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,720

Underlying: Common Stock · 207,720 shares

Expires 2033-03-15

F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026.

SEC source: 0001673232-26-000012 · primarydocument.xml · derivative · entry 3

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,790

Underlying: Common Stock · 17,790 shares

Expires not disclosed

F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001673232-26-000012 · primarydocument.xml · derivative · entry 2

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,592

Underlying: Common Stock · 15,592 shares

Expires not disclosed

F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001673232-26-000012 · primarydocument.xml · derivative · entry 1

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,720

Underlying: Common Stock · 99,720 shares

Expires 2033-03-15

F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026.

SEC source: 0001636178-26-000001 · primarydocument.xml · derivative · entry 3

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,380

Underlying: Common Stock · 10,380 shares

Expires not disclosed

F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001636178-26-000001 · primarydocument.xml · derivative · entry 2

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,098

Underlying: Common Stock · 9,098 shares

Expires not disclosed

F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001636178-26-000001 · primarydocument.xml · derivative · entry 1

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,170

Underlying: Common Stock · 58,170 shares

Expires 2033-03-15

F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · derivative · entry 17

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,000

Underlying: Common Stock · 8,000 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F8 · price: This transaction was executed in multiple trades at prices ranging from $225.33 to $225.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 473

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F7 · price: This transaction was executed in multiple trades at prices ranging from $224.33 to $225.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,565

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F6 · price: This transaction was executed in multiple trades at prices ranging from $223.24 to $224.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,152

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $222.24 to $223.155. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,554

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $221.21 to $222.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,363

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $220.025 to $220.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,005

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $219.02 to $219.975. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-004837 · form4-03142023_040301.xml · derivative · entry 21

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,000

Underlying: Common Stock · 8,000 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

SEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 17

ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023.

F15 · price: This transaction was executed in multiple trades at prices ranging from $232.53 to $233.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.